Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Acute Lymphoblastic Leukaemia (ALL): Update Bulletin # 1 [February 2019]

Product Code:
596201091
Publication Date:
February 2019
Format:
PDF
Price:
$1,315

Gain new key opinion leader (KOL) insights on the latest events happening in acute lymphoblastic leukaemia. (ALL). Topics covered include expert views on the expanded indication for Blincyto (blinatumomab) monotherapy in Europe. The KOLs also shared their views on updated clinical data presented from the ZUMA-3 Phase I/II study evaluating KTE-X19. Finally, the KOLs imparted their views on longer-term analyses announced from pivotal ELIANA and JULIET studies of Kymriah (tisagenlecleucel).

Business Questions:

• How have KOLs received the news of Blincyto’s expanded indication?
• What impact will Blincyto’s expanded indication have on prescribing of Blincyto?
• What concerns, if any, do KOLs have regarding the use of Blincyto in the MRD-positive setting?
• What are KOL views on the new data presented from the ZUMA-3 trial?
• In which treatment setting do KOLs anticipate KTE-X19 will have the greatest potential?
• What concerns, if any, do KOLs have regarding the use of KTE-X19?
• How do KOLs view the longer-term data from the ELIANA and JULIET trials?
• What questions remain regarding the long-term outcomes of treatment with Kymriah?
• What challenges do KOLs highlight regarding the use of Kymriah?




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved